Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase...
20 insider purchases on record · latest filing 2025-03-07.
Insiders have also filed 73 sale transactions at TNYA.